| No ACE pre-treatment | ACE-pre-treatment | P |
---|---|---|---|
 | N = 79 | N = 28 |  |
Duration in days, median (range) | Â | Â | Â |
   current episode | 121 (74–178) | 96 (59–135) | ns |
   total AF duration | 161 (105–247) | 117 (63–160) | ns |
Number of previous ECVs, N(range) | 1 (0–5) | 1(0–3) | ns |
Underlying heart disease * (%) | Â | Â | Â |
   Left ventricular dysfunction | 14% | 40% | 0.01 |
   Hypertension | 24% | 46% | 0.03 |
   Valve disease | 19% | 21% | ns |
   Coronary artery disease | 18% | 36% | 0.07 |
   Lone AF | 17% | 14% | ns |
Echocardiography (mm ± SD) |  |  |  |
   LA parasternal long axis | 46 ± 7 | 50 ± 10 | 0.03 |
   LA 4 chamber view long axis | 66 ± 9 | 67 ± 12 | ns |
   LA 4 chamber view short axis | 45 ± 8 | 49 ± 10 | ns |
   RA 4 chamber view long axis | 61 ± 8 | 64 ± 7 | ns |
   LVEDD | 49 ± 7 | 54 ± 8 | 0.01 |
   LVESD | 34 ± 9 | 38 ± 12 | ns |
Medication | Â | Â | Â |
   Beta blocker | 51% | 47% | ns |
   Calcium channel blocker | 35% | 39% | ns |
   Digoxin | 45% | 51% | ns |
   Diuretics | 29% | 34% | ns |
   Angiotensin receptor blocker | 1% | 0% | ns |